ATOS Insider Trading Activity and SEC Form 4 Filings
ATOS insider trading summary
No open-market insider purchases or sales of Atossa Therapeutics, Inc. (ATOS) have been reported on SEC Form 4 in the past 12 months.
Latest ATOS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 21, 2025 | Steven C Quay | President & CEO | Buy | $10K (11,239 @ $0.88) |
| Mar 26, 2025 | H. Lawrence Remmel | Insider | Buy | $7K (10,000 @ $0.70) |
| Apr 10, 2024 | Jonathan Finn | Insider | Buy | $44K (25,000 @ $1.77) |
| Nov 15, 2023 | Gregory L Weaver | Former EVP, CFO, & Director | Sell | $33K (50,000 @ $0.65) |
| Jun 20, 2023 | Gregory L Weaver | EVP & CFO | Buy | $49K (50,000 @ $0.97) |
| Jul 2, 2021 | Gregory L Weaver | Director | Sell | $600K (107,497 @ $5.58) |
| Nov 15, 2017 | Kyle Guse | CFO, Gen Counsel and Secretary | Buy | $471 (1,400 @ $0.34) |
| Nov 15, 2017 | Kyle Guse | CFO, Gen Counsel and Secretary | Buy | $3K (8,600 @ $0.34) |
| Apr 17, 2017 | H. Lawrence Remmel | Director | Buy | $2K (2,500 @ $0.63) |
| Apr 1, 2016 | H. Lawrence Remmel | Director | Buy | $495 (1,500 @ $0.33) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.